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Abstract
Background: Angiogenesis is a process by which new capillaries are formed from pre-existing
blood vessels in physiological (e.g., exercise, wound healing) or pathological (e.g., ischemic limb as
in peripheral arterial disease, cancer) contexts. This neovascular mechanism is mediated by the
vascular endothelial growth factor (VEGF) family of cytokines. Although VEGF is often targeted in
anti-angiogenic therapies, there is little knowledge about how its concentration may vary between
tissues and the vascular system. A compartment model is constructed to study the VEGF
distribution in the tissue (including matrix-bound, cell surface receptor-bound and free VEGF
isoforms) and in the blood. We analyze the sensitivity of this distribution to the secretion rate,
clearance rate and vascular permeability of VEGF.
Results: We find that, in a physiological context, VEGF concentration varies approximately linearly
with the VEGF secretion rate. VEGF concentration in blood but not in tissue is dependent on the
vascular permeability of healthy tissue. Model simulations suggest that relative VEGF increases are
similar in blood and tissue during exercise and return to baseline within several hours. In a
pathological context (tumor), we find that blood VEGF concentration is relatively insensitive to
increased vascular permeability in tumors, to the secretion rate of VEGF by tumors and to the
clearance. However, it is sensitive to the vascular permeability in the healthy tissue. Finally, the
VEGF distribution profile in healthy tissue reveals that about half of the VEGF is complexed with
the receptor tyrosine kinase VEGFR2 and the co-receptor Neuropilin-1. In diseased tissues, this
binding can be reduced to 15% while VEGF bound to the extracellular matrix and basement
membranes increases.
Conclusion:  The results are of importance for physiological conditions (e.g., exercise) and
pathological conditions (e.g., peripheral arterial disease, coronary artery disease, cancer). This
mathematical model can serve as a tool for understanding the VEGF distribution in physiological
and pathological contexts as well as a foundation to investigate pro- or anti-angiogenic strategies.
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Background
Angiogenesis is the process by which new blood vessels
grow from pre-existing vascular networks. This is a
dynamic physiological mechanism (e.g., during wound
healing, exercise training) but has been shown to be
involved in pathological conditions such as age-related
macular degeneration, rheumatoid arthritis, diabetic
retinopathy, peripheral arterial disease, and cancer [1].
Vascular endothelial growth factor (VEGF) is a potent
cytokine involved in angiogenesis [2]. This growth factor
plays a role in transcapillary permeability and stimulates
cell differentiation, proliferation, migration and survival.
The human VEGF gene family is composed of five mem-
bers. VEGF-A (also commonly referred as VEGF) and
VEGF-B are known to be involved in angiogenesis. VEGF-
A and three members (VEGF-C, VEGF-D and placental
growth factor PlGF) have been shown to be implicated in
both mechanisms. The VEGF-A family contains the differ-
ent splice isoforms VEGF121, VEGF121b, VEGF145,
VEGF145b, VEGF148, VEGF162, VEGF165, VEGF165b,
VEGF183, VEGF189, VEGF206, VEGF232 [3]. The major splice
variants are VEGF121, VEGF165, VEGF189  and VEGF206.
Because the role of VEGF189 and VEGF206 in vivo is not
well understood and their expression is low compared to
VEGF121 and VEGF165 [3], we consider the two main iso-
forms VEGF121 and VEGF165 in our model. These two lig-
ands bind two receptor tyrosine kinases VEGFR1 (Flt-1,
fms-like tyrosine kinase-1) and VEGFR2 (Flk-1/KDR, fetal
liver kinase-1/Kinase Domain-containing Receptor). The
VEGF165  isoform binds to a non-signaling co-receptor
called Neuropilin-1 (NRP1) and to heparan sulfate prote-
oglycans which are constituents of the extracellular matrix
(ECM) and the cellular basement membranes. NRP1 also
independently couples with VEGFR1, to which VEGF121
can bind to form a complex of all three. Another complex
can be formed when VEGF165 bound to NRP1 binds in
turn to VEGFR2 (or vice versa).
VEGF interactions with these receptors in the context of
angiogenesis have been extensively studied using compu-
tational models. For example, it was predicted that block-
ade of NRP1-VEGFR coupling would be a good strategy to
decrease VEGF-VEGFR2 signaling [4]. Other simulations
showed that VEGFR heterodimers comprise 10–50% of
the active, signaling VEGF receptor complexes, and that
heterodimers form at the expense of homodimers of
VEGFR1 when VEGFR2 populations are larger [5]. How-
ever, in the absence of in vivo data, we do not include het-
erodimers in the model. Insights into the distribution of
VEGF in tissues in vivo have been made; for example, it
was predicted that the majority of the VEGF in muscle is
bound to the cell surface receptors or to the extracellular
matrix and that NRP1 enhances the binding of VEGF165 to
VEGFR2 [6]. The models have also been used to design
and test therapeutic approaches; for example, in periph-
eral arterial disease, exercise training results in increased
VEGF secretion in hypoxic tissue and augmented VEGF
receptor expression, and multi-scale computational mod-
els revealed that this leads to an increase in both VEGF
concentration and VEGF gradients, a potentially effective
therapeutic approach [7]. Anatomically detailed tissue
models have predicted heterogeneity in the activation of
the endothelial VEGF receptors and how this affects VEGF
gradients [8]. Similarly, in hypoxic tissues, the high spatial
heterogeneity of muscle fiber VEGF secretion leads to sig-
nificant gradients of VEGF concentration and VEGF recep-
tor activation in both resting and exercising muscle [9].
Three-dimensional VEGF distribution was also predicted
in ischemic muscle in a model of peripheral arterial dis-
ease [10].
A meta-analysis of VEGF levels in healthy subjects and
cancer patients revealed that plasma VEGF levels are sev-
eral-fold higher in cancer [11]. This conclusion should be
taken cautiously since VEGF levels vary with the tumor
type, size and location; also, the ranges of VEGF in control
subjects and cancer patients in some studies overlap.
Plasma VEGF is also elevated during exercise [12,13] and
in peripheral arterial disease [14]. To investigate the distri-
bution of VEGF in human subjects under physiological
and pathological conditions, we formulate a biophysi-
cally-accurate compartment model to describe the entire
human body. Blood is represented by one compartment
that communicates with two others representing healthy
and diseased tissues. A sensitivity analysis is performed to
investigate the role of parameters including secretion rate,
clearance rate and vascular permeability of VEGF. The for-
mulation is general and the model can be applied to both
healthy human subjects and to subjects with a diseased
tissue, e.g., ischemic limb or tumor. As an illustration, we
consider a compartment representing a tumor to investi-
gate the possible causes of the several-fold increase
observed in plasma VEGF levels in cancer patients [11].
The formulated model provides a foundation for studying
various diseases where information about VEGF distribu-
tion in the body is important. It will also serve as a basis
for simulating pro- and anti-angiogenic VEGF-related
therapeutic procedures.
Methods
Geometry
As a first approximation, a tissue can be represented as a
collection of capillaries (and small arterioles and
venules), surrounded by parenchymal cells. For example,
skeletal muscle is constituted of long fibers whose cross
sections are approximately constant. A schematic of this
configuration is shown in Figure 1A. Note that the stromal
cells are not considered explicitly in the model, but rather
lumped with parenchymal cells. Between the parenchy-
mal cells and the capillaries lies the interstitial space com-BMC Systems Biology 2008, 2:77 http://www.biomedcentral.com/1752-0509/2/77
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Compartment model of VEGF transport in blood and tissues Figure 1
Compartment model of VEGF transport in blood and tissues. A, Schematic of a tissue cross section. VEGF165 can bind 
to glycosaminoglycan chains (GAG) and be sequestered in the extracellular matrix whereas VEGF121 cannot. The isoforms have 
different cell surface receptor binding profiles. B, Compartment model set-up. Three compartments are used in our simula-
tions: blood, healthy and diseased tissues. The diseased tissue compartment is not used in all simulations. VEGF is secreted by 
parenchymal cells in the healthy and diseased compartments (q). VEGF transport between the blood and the tissue compart-
ments is via transcapillary permeability (kp). VEGF receptors are expressed on the abluminal side of the endothelial cells and 
VEGF binding to these receptors can lead to internalization (kint). Plasma clearance for VEGF is present in the blood compart-
ment (cV). C, Interactions between VEGF, cell surface receptors, extracellular matrix and basement membranes. VEGF121 binds 
to VEGFR2 but does not bind to NRP1. VEGF165 interacts with VEGFR2 or NRP1. Once bound, it can form a ternary complex 
VEGFR2- VEGF165- NRP1. VEGF165 can be sequestered by the ECM, PBM or EBM by binding to GAG chains. VEGF121 binds to 
VEGFR1. This receptor couples with NRP1 to form VEGFR1-NRP1 complex or the ternary complex VEGF121-VEGFR1-NRP1 
if previously occupied by VEGF121. VEGF165 also binds to VEGFR1 but not to the VEGFR1-NRP1 complex. The receptors 
(VEGFR1, VEGFR2 and NRP1) are inserted or internalized at the cell surface.BMC Systems Biology 2008, 2:77 http://www.biomedcentral.com/1752-0509/2/77
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posed of the extracellular matrix (ECM), parenchymal
basement membranes (PBM) and endothelial basement
membranes (EBM). In this study, these anatomical struc-
tures will be represented in a spatially-averaged manner:
each structure will be represented by a distinct volume
with specific VEGF binding properties, but VEGF gradients
within the volume will not be considered.
Computational model
We constructed a compartment model of VEGF transport
and interactions with cell receptors representing the
whole human body that is an extension of previous one-
compartment models for breast tumor tissue [4] and skel-
etal muscle [6]. This design can also be used to describe
any animal if the parameters to characterize the tissues
and blood are available. In physiological cases, we con-
sider two compartments: tissue and blood. VEGF trans-
port between the compartments is mediated by
transcapillary permeability. In pathological cases, a third
compartment represents the diseased tissue, e.g., a tumor
in cancer or ischemic tissue in peripheral arterial disease
(Figure 1B). Again vascular permeability allows free VEGF
to move between the blood and the diseased tissue.
Because the interacting surface between the healthy and
the diseased tissues is, in most cases, much smaller than
the trans-endothelial exchange surface between each tis-
sue and blood, we do not include VEGF transport between
the normal and diseased tissue directly. This additional
parameter could be included in further studies.
Leaving aside the vascular system, the tissues of the body
can be divided into two main groups: skeletal muscle
(35%) [15] and the rest of the body (e.g., brain, heart,
liver, kidney, bones, fat). As a first approximation, we
assume that the rest of the body has the same characteris-
tics as skeletal muscle. This assumption can be relaxed by
formulating progressively more detailed compartment
models containing different organs and tissues; however,
the parameters describing VEGF-binding properties of dif-
ferent tissues are currently unavailable. Therefore, the
healthy tissue compartment in the present model has the
mass of the whole body (minus the blood) and the den-
sity of the skeletal muscle.
The interstitial space between the parenchymal cells and
the vascular endothelial cells can be divided into three
regions: the extracellular matrix (ECM), the basement
membrane surrounding the parenchymal cells (PBM) and
the basement membrane surrounding the endothelial
cells (EBM). The two isoforms of the VEGF-A family con-
sidered in the model are the freely diffusible heparin-
binding VEGF165 (VEGF164 in rodents) and non-heparin-
binding VEGF121 (VEGF120 in rodents). Because VEGF165
binds to the heparan sulfate proteoglycans (HSPGs) that
constitute a major component of the extracellular matrix
and basement membranes, this isoform can be seques-
tered by the ECM and by cellular basement membranes.
We assume that the distribution of unbound (free) VEGF
in the interstitial space is uniform within each compart-
ment and spatial variability due to gradient formation is
neglected [4,6,16].
The interactions between VEGF121 and VEGF165 and their
receptors (VEGFR1, VEGFR2 and NRP1) are illustrated in
Figure 1C and will be further described in the equation
section. To summarize, VEGF121 and VEGF165 bind to both
VEGFR1 and VEGFR2 but only VEGF165 is believed to bind
to the non-enzymatic co-receptor NRP1. The receptors are
inserted or internalized as illustrated in Figure 1C. We
assume that the receptors are only present on the ablumi-
nal side of the blood vessels and therefore are only
exposed to interstitial VEGF levels of the tissue compart-
ments, though this assumption can be easily relaxed in the
future. Although there is some qualitative evidence that
receptors are present on the luminal side [17], to our
knowledge, there is currently no quantitative data on the
levels of receptor expression on the luminal vs. abluminal
side of the endothelium.
VEGF molecules are secreted by the parenchymal cells
present in the tissue. Depletion of VEGF molecules occurs
if the cell surface receptor (VEGFR1, VEGFR2 or NRP1)
that VEGF is bound to is internalized into the cellular
membrane. The free molecules diffuse within the availa-
ble interstitial fluid although here this diffusion is
assumed to be fast compared to the biochemical reac-
tions, the compartment well-mixed and the distribution
of molecules uniform; the justification for this assump-
tion was presented in [7] by estimating that the Damkoh-
ler number (ratio of diffusion time to reaction time) is
significantly less than one. Free VEGF is transported by
transcapillary permeability between the blood and tissue
compartments and cleared from the blood (e.g., by the
kidneys and liver).
Equations
The changes in species concentration over time are gov-
erned by mass balance relationships and represented by a
system of coupled nonlinear ordinary differential equa-
tions; the details of the derivation are given in our previ-
ous publications [4,6,16]. Although the kinetics and
properties may be different, the healthy and diseased tis-
sues are governed by the same equations and constituted
by the same molecular species. Therefore, unless specified
otherwise, the following equations govern both healthy
and diseased tissues. The biological and physical proper-
ties of the tissue, VEGF secretion rates and vascular perme-
ability may vary between the normal and diseased tissues;
the values of the parameters will be specified in a later sec-
tion.BMC Systems Biology 2008, 2:77 http://www.biomedcentral.com/1752-0509/2/77
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Each tissue compartment can be divided into subcompart-
ments where distinct reactions take place: cell surfaces and
interstitial space, the latter further subdivided into availa-
ble interstitial fluid, ECM, PBM and EBM. Interstitial spe-
cies include free VEGF, VEGF binding sites in the matrix
and the complexes they form. Surface species consist of
free receptors or VEGF-ligated receptors on the vascular
endothelial abluminal surface. Unless specified other-
wise, the concentrations of the interstitial and blood spe-
cies are expressed per unit volume of the corresponding
subcompartment (e.g., available fluid volume of the inter-
stitial space, ECM, PBM or EBM) while the concentrations
of the surface species are expressed per unit surface area of
the corresponding cell (though it is possible to intercon-
vert the units).
Interstitial space
We use the following notation: [M] is the concentration of
VEGF binding sites of the ECM, PBM or EBM (the location
is denoted by the corresponding subscript, e.g., [MECM]);
[V] represents the concentration of any unbound VEGF
isoform (unless specified by a subscript, e.g., [V121]) in the
available interstitial fluid; kon and koff the kinetic rates for
binding and unbinding respectively. In the interstitium of
the normal and diseased tissues, the following reactions
take place
and are governed by the equations
Cell surface
[R], [N] and [RN] represent the densities of the unoccu-
pied receptor tyrosine kinases (VEGFR1, VEGFR2), the
unoccupied co-receptor (NRP1), and their coupled com-
plexes (VEGFR1 coupled with NRP1), respectively; [VR]
and [VN] are the concentrations of VEGF bound to the
VEGF receptors and NRP1, respectively; [RVN] (or [VRN])
is the concentration of VEGF-bound in the form of the ter-
nary complex (VEGFR2-VEGF165-NRP1 or VEGF121-
VEGFR1-NRP1). sR represents the rate at which the recep-
tors are inserted into the cell membrane and kint the inter-
nalization rate of the receptors.
The VEGF165 isoform interacts with the receptors through
the following reactions
while the VEGF121 isoform binds to the receptors accord-
ing to these reactions
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The 10 preceding chemical reactions are governed by the
following equations:
Ligands in the tissue compartments
The ligands VEGF121 and VEGF165 are secreted by the cells
at a rate qV per unit volume of total tissue. The secretion
rate is assumed to be constant. The concentrations of the
ligands in tissue follow these equations:
Note that, here, the vascular permeability has yet to
appear in the equations.
Transport between the compartments
When two tissue volumes containing different amount of
extracellular matrix are separated by a semipermeable
membrane (endothelium), in thermodynamic equilib-
rium the volume concentrations of ligand would not be
the same. To correctly describe this phenomenon, a volu-
metric correction has to be made in order to take into
account that VEGF can move only in a restricted region in
the interstitial space. We follow the formalism introduced
by Truskey et al. to describe macromolecular drug distri-
bution in tissue [18]. The extracellular matrix is a porous
medium composed of proteins and polysaccharides and
can deform under mechanical stress. This deformation
can affect the volume accessible to the solutes. In addi-
tion, some pores are inaccessible to the freely diffusible
molecules, because of their sizes or because of the tissue
configuration. Finally, there is a steric exclusion of solutes
near the surface of the solid phase of the extracellular
matrix and the basement membranes. To reflect these
properties in the model, the following parameters are
introduced: Φ the partition coefficient, εIF the porosity, εIS
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the interstitial fraction, f the fluid fraction of the intersti-
tial space and KAV the available volume fraction. These
parameters are defined by and related to one another
through the following equations:
The free VEGF molecules that diffuse in the interstitial
space are effectively only present in the available intersti-
tial fluid volume. In other words, the interstitial space is a
part of the total tissue volume U and has a volume of εIS ×
U . It is composed of a solid phase of volume (εIS - εIF) ×
U and a fluid phase of volume εIF × U in which VEGF can
circulate freely. However, given the pore size of the ECM
and basement membranes and the molecular radius of
VEGF, some regions are excluded because the growth fac-
tor molecules cannot access them. In conclusion, the
VEGF molecules can diffuse in the available interstitial
fluid volume UAV = KAV × U . Similarly, the free VEGF con-
centration in the available interstitial fluid volume, noted
[V]AV, is related to the free VEGF concentration in the total
tissue volume [V] by  .
Until now, all the equations have been expressed per unit
volume of total tissue. However, because of volume exclu-
sion, we now introduce explicit available interstitial vol-
umes. We assign the subscripts N for healthy (or normal)
tissue, D for diseased tissue, B for blood and p for blood
plasma (available fluid volume to VEGF in the blood).
Note that these subscripts are written as superscripts in the
kinetic parameters for clarity reasons. The transport of free
VEGF molecules from normal tissue to the blood occurs at
a rate   (units: cm/s). The term   reads as "rate of
permeability (kp) of VEGF (V) from the normal tissue
compartment (N) to the blood (B)". The free VEGF mole-
cules extravasate at a rate   (units: cm/s). The interface
between the normal tissue and the blood is the total sur-
face of the microvessels denoted as SNB (units: cm2).
Note that, [V]AV × UAV = [V] × U in the tissue compart-
ments and [V]p × Up = [V]B × UB in the blood compartment.
Equation (20) can be rewritten in terms of moles per unit
volume of total tissue
VEGF binding to the receptors, the extracellular matrix
and the basement membranes (Eq. (18) and (19)) are
added leading to the full equations governing each free
isoform in the normal tissue:
Similarly, in the diseased tissue compartment, VEGF121
and VEGF165 are secreted by cells at a rate qV . The secretion
rate is assumed constant. Free VEGF ligands can enter the
blood at a rate   and extravasate at a rate  . The
interface between the diseased tissue and the blood is the
total surface of the microvessels denoted as SDB. The equa-
tions governing each VEGF isoform read:
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We assume that no receptors are present on the luminal
side of the endothelial cells. Therefore, only free ligands
exist in the blood compartment. Nevertheless, receptors
in this compartment could be added to the model as
experimental knowledge emerges and the density of
receptors on the luminal side of the endothelial cells is
quantified. The presence of platelets and leukocytes as
potential VEGF carriers, is neglected in the current model
as well as soluble VEGFR1 (sFlt) as a VEGF-neutralizing
molecule. Given the complexity of the model, it is prefer-
able to introduce additional factors one at a time and
investigate their effects (a computational equivalent of
knock-in or knock-out procedures). The model can be
readily extended to include these factors.
Finally, in the blood compartment, VEGF is cleared at a
rate cV (units: s-1) per unit volume of total blood via sev-
eral organs (e.g., kidneys) that are not explicitly repre-
sented here. This process is described as a first-order
reaction. Similarly to the equations for free VEGF in nor-
mal and diseased tissues, the governing equation for each
free isoform in the blood is:
This can be rewritten per unit volume of whole blood by:
Therefore, the VEGF isoforms are governed by the two fol-
lowing equations.
Whole-body parameters
Each tissue is uniquely characterized by its biochemical,
biophysical and geometrical properties as input parame-
ters into the model. Similar to the consideration of total
tissue volume compared to available interstitial fluid vol-
ume, we distinguish between the total tissue volume of
the ECM, PBM and EBM, noted UECM, UPBM, UEBM respec-
tively, and the available interstitial fluid volumes of the
ECM, PBM and EBM, noted UAV, ECM, UAV, PBM, UAV, EBM
respectively. In terms of these variables various tissue
characteristics can be calculated for the different tissue
compartments, e.g., the total amount of VEGF165 bound
to the binding sites of the ECM is equal to UAV, ECM ×
[V165MECM]AV, where [V165 MECM]AV is the concentration of
VEGF165 bound to the ECM in moles per liter of available
ECM fluid volume. Similarly, the total amount of VEGF165
sequestered by the EBM is equal to UAV,  EBM  ×
[V165MEBM]AV, where [V165MEBM]AV is the concentration of
VEGF165 bound to the endothelial basement membrane in
moles per liter of available EBM fluid volume. The conver-
sion is given by
UAV, EBM [MEBM]AV = [MEBM] U (30)
UAV, ECM [MECM]AV = [MECM] U (31)
In addition, the total abluminal surface area of endothe-
lial cells is SEC. The total amount of unligated VEGFR2 is
[R2]* × SEC, where [R2]* is the number of receptors
VEGFR2 per unit of endothelial surface.
[R2]* SEC = [R2] U (32)
Note that the kinetic rates can also be transformed, e.g.,
kAV, onU = k onUAV (33)
In the blood phase, we express all concentrations with
respect to its total volume. If we designate red blood cell
fractional volume or hematocrit as Ht and neglect the
small volume of white blood cells and platelets, then the
dV D
dt
qk VRk V V
D
on V R
D
DD off V R
D 121
121 121 1 121 1 121 1 12
[]
=− [] [ ] + ,, , 1 11
121 1 1 121 1 1 121 1 1 121 1
R
k V RN k V RN
D
on V R N
D
DD off V R N
D
[]
− [] [ ] + ,, , 1 1
121 2 121 2 121 2 121 2
[]
− [] [ ] + []
−
D
on V R
D
DD off V R
D
D
pV
DB
kV R kV R
k
,, ,
S SDB
UD
V D
KAV D
k
SDB
UD
UB
Up
V pV
BD
B
121
121
[]
+ []
,
(24)
dV D
dt
qk VM k V
D
on V MEBM
D
D EBM D off V M
165
165 165 165 165
[]
=− [] [] + ,, ,, E EBM
D
EBM D
on V MECM
D
D ECM D off V MEC
VM
kV M k
165
165 165 165
[]
− [] [ ] + ,, , M M
D
ECM D
on V MPBM
D
D PBM D off V MPBM
D
VM
kV M k
165
165 165 165
[]
− [] [] + ,, , V VM
kV R kV R
PBM D
on V R
D
D D off V R
D
165
165 1 165 1 165 1 165 1
[]
− [] [] + [] ,, , D D on V R
D
D D
off V R
D
D on V
kV R
kV R k
− [] []
+ [] −
,,
,,
165 2 165 2
165 2 165 2 165, ,, N
D
D D off V N
D
D
pV
DB
VN k V N
k
SDB
UD
V D
K
1 165 1 165 1 165 1
165
[] [] + []
− []
A AV D
k
SDB
UD
UB
Up
V pV
BD
B ,
+ [] 165
(25)
U
dVp
dt
kS V kS
V N
KAV N
kS V k pp V
BN
NB p pV
NB
NB pV
BD
DB p pV
[]
=− [] + []
− [] +
,
D DB
DB S
V D
KAV D
[]
,
(26)
dVB
dt
k
SNB
Up
Vk
SNB
UB
V N
KAV N
k
SDB
Up
V pV
BN
B pV
NB
pV
BD
B
[]
=− [] + []
− []
,
+ + []
k
SDB
UB
V D
KAV D
pV
DB
,
(27)
dV B
dt
cV k
SNB
Up
Vk
SNB
UB
V
V B pV
BN
B pV
NB 121 121
121 121 121
[]
=− [] − [] + [ ] ]
− [] + []
N
KAV N
k
SDB
Up
Vk
SDB
UB
V D
KAV D
pV
BD
B pV
DB
,
,
121
121
(28)
dV B
dt
cV k
SNB
Up
Vk
SNB
UB
V
V B pV
BN
B pV
NB 165 165
165 121 165
[]
=− [] − [] + [ ] ]
− [] + []
N
KAV N
k
SDB
Up
Vk
SDB
UB
V D
KAV D
pV
BD
B pV
DB
,
,
165
165
(29)BMC Systems Biology 2008, 2:77 http://www.biomedcentral.com/1752-0509/2/77
Page 9 of 25
(page number not for citation purposes)
concentration of species in blood can be expressed in
terms of plasma concentrations as follows
[V165]p = [V165]B × (1 - Ht) (34)
where [V165]p represents the concentration of free VEGF165
in the plasma.
Numerical implementation
The model, represented by 40 ordinary differential equa-
tions (19 for each tissue compartment and 2 for the
blood) and initial conditions, was implemented using
Visual FORTRAN 6 software on a PC. The equations were
non-dimensionalized prior to numerical solution using
appropriate characteristic values and once the solutions
were obtained were transformed to the original dimen-
sional variables. Transient solutions were calculated using
an adaptive step-size Runge-Kutta 5th-order accuracy inte-
grative scheme. A relative error tolerance of 10-5 was used.
The steady state was defined when the concentrations
changed by less than 1%.
Model parameters
The parameters are summarized in Tables 1, 2, 3, 4, 5, 6.
Blood
We consider a human subject of 70 kg. To calculate the
typical plasma and total blood volumes in a 70-kg human
being, we used a study of ninety healthy subjects by Gib-
son and Evans [19]. The volumes were plotted against the
weight of the volunteer. Linear regression was performed
for males and females and both volumes were determined
for 70 kg. We therefore consider 5.154 liters of total blood
including 2.920 liters of blood plasma, which constitute
56.7% of total blood volume.
Normal tissue
The volume of the normal tissue is the volume corre-
sponding to a 70-kg subject with a vastus lateralis skeletal
muscle density of 1.06 g/cm3, less 5154 cm3 of whole
blood (mass of blood is 5.164 kg for whole blood density
of 1,002 g/L [20]). The parameters characterizing the
healthy tissue (skeletal muscle) are summarized in Tables
1, 2, 3 and the properties and characteristics of the skeletal
muscle have been described in [6]. However, a few adjust-
ments were made. The interstitial space is composed of
14.175% of collagen (in the ECM and basement mem-
branes) [21]. This content is not accessible to the VEGF
molecules and thus does not account for the available
interstitial fluid volume. Interstitial fluid of muscle has
been measured at 7% of tissue volume [6], thus the total
interstitial space is 8.16% (Table 1). The pore sizes of the
basement membranes and the extracellular matrix in the
skeletal muscle are estimated at 7 nm [20] and 66 nm [19]
respectively. For a molecular weight of 45 kDa (VEGF
molecule), this corresponds to a partition coefficient Φ of
0.35 and a KAV of 0.0245 for the PBM and EBM [22] and a
partition coefficient of Φ of 0.9 and a KAV of 0.063 for the
ECM [22]. The available volumes for VEGF transport in
the extracellular matrix, parenchymal basement mem-
brane and endothelial basement membrane are therefore
0.061987, 0.000307, and 0.000087 cm3/cm3  tissue,
respectively (Table 1).
For the VEGF receptors, we assume that, at any instant, the
insertion of receptors equals the internalization. As a
result, the number of total (free and bound) receptors is
conserved. This condition also applies to the diseased tis-
sue. Regulation of VEGF receptors represents an important
poorly explored area; more complex receptor dynamics
can be considered in the model as experimental informa-
tion becomes available.
Diseased tissue
As an example of diseased tissue, we consider a 4 cm-
diameter breast tumor. For this tissue, we use parameters
reported in a previous one-compartment model [4].
Assuming the tumor to be a sphere, the volume of the dis-
eased compartment is 33 cm3. The parameters are summa-
rized in Tables 4, 5, 6 and the properties and
characteristics of the tumor tissue have been described in
[4]. The 5% collagen content increases the interstitial
space from 58.0% [4] to 61.1%. In breast tumor, the pore
size of the endothelial basement membrane has been
measured to be several hundred nanometers (200 nm
[23] and between 400–600 nm [24]) which corresponds
to a partition coefficient of 0.9 [22]. It was shown that the
basement membranes and the ECM are similar and diffi-
cult to distinguish in the context of mammary tumor [25].
Therefore, a partition coefficient of 0.9 was also adopted
for the ECM (same partition coefficient as in the vastus
lateralis skeletal muscle) and the PBM. This corresponds
to a KAV of 0.522 for the three regions [22]. The available
interstitial fluid volumes for VEGF transport in the extra-
cellular matrix, parenchymal and endothelial basement
membranes are therefore 0.519308, 0.002446, and
0.000270 cm3/cm3 tissue, respectively.
Permeability between the normal tissue and the blood
To determine the permeability between the normal tissue
and the capillaries, we first determine the Stokes-Einstein
radius for a VEGF molecule. The molecular weight of
VEGF165 isoform is approximately 45 kDa. The Stokes-
Einstein radius ae (in Å) is calculated by the formula for
globular molecules given in Venturoli and Rippe [26]: ae =
0.483 × (MW)0.386 . For 45 kDa, we thus find a Stokes-Ein-
stein radius of 30.2 Å. With this effective molecular radius,
it is then possible to determine the permeability-surface
area product [27] as 2.5 × 10-4 mL/s × 100 g. With a surface
area of 70 cm2/g [27], we deduce that the permeabilityBMC Systems Biology 2008, 2:77 http://www.biomedcentral.com/1752-0509/2/77
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between the normal tissue and the blood is 4.3 × 10-8 cm/
s. A similar value was found using the permeability-sur-
face area product using Schmittmann and Rohr's study
[28]. Because there is paucity of experimental data on
VEGF-dependence of macromolecular permeability
[29,30], we consider a permeability range from 4 × 10-9 to
4 × 10-6 cm/s for sensitivity analyses; this range includes
the 2–3 fold VEGF-dependent increase in permeability
reported in [29,30]. When the permeability between the
normal tissue and the blood is fixed, the value 4 × 10-8 cm/
s is selected. The VEGF transport is assumed to be passive.
Permeability between the diseased tissue and the blood
For the permeability between the tumor and the blood,
we note that ovalbumin and the VEGF homodimer have a
similar molecular weight (45 kDa). In human tumor
xenografts, the microvascular permeability for ovalbu-
min, a globular molecule, was measured to be 5.77 × 10-7
cm/s [24]. Studies of tumor microvascular permeability
for macromolecules in vivo also provide useful insights
[31]. However, most of these experiments use dextrans
that are linear molecules contrary to VEGF. This difference
is crucial for permeability purposes. To resolve this issue,
the relationship between the Stokes-Einstein radius and
the permeability is usually preferred. For a Stokes-Einstein
radius of about 30.2 Å (30.8 Å for ovalbumin), the perme-
ability is around 6 × 10-7 cm/s [24]. Therefore, a range
from 4 × 10-8 to 4 × 10-5 cm/s is chosen for the vascular
permeability to VEGF in tumor when the sensitivity anal-
ysis is performed since little data on VEGF-dependence to
Table 1: Geometric parameters for the healthy tissue (human vastus lateralis muscle)
Skeletal muscle characteristic Value Unit Reference
Muscle fibers
Cross sectional area of one fiber 3000 μm2 [6]
Perimeter of one fiber 222 μm[ 6 ]
Capillary-fiber ratio 1.38 [37]
Capillary density 420 capillaries/mm2 tissue [6]
Muscle fiber density 304 fibers/mm2 tissue [6]
Volume fractions
Interstitial space 8.16% cm3/cm3 tissue [38,39]
Fibers 89.98% cm3/cm3 tissue [6]
Microvessels 1.86% cm3/cm3 tissue [6]
of which vascular space 1.4% cm3/cm3 tissue [40]
Microvessels
Internal diameter of microvessel 6.56 μm[ 6 ]
Thickness of endothelial cell 0.5 μm[ 4 1 ]
External diameter of microvessel 7.56 μm[ 6 ]
Cross sectional area of one microvessel 45 μm2 [6]
Perimeter of one microvessel 26 μm[ 6 ]
Surface areas
Muscle fibers 664 cm2/cm3 tissue [6]
Microvessels 108 cm2/cm3 tissue [6]
Basement membranes (BM)
Thickness of muscle fiber BM 24 nm [42]
Basement membrane volume (muscle fiber) 0.00159 cm3/cm3 tissue Calculated
of which available to VEGF 0.000307 cm3/cm3 tissue Calculated
Thickness of microvessel BM 43 nm [42]
Basement membrane volume (microvessel) 0.00045 cm3/cm3 tissue Calculated
of which available to VEGF 0.000087 cm3/cm3 tissue Calculated
Extracellular matrix volume 0.07951 cm3/cm3 tissue Calculated
of which available to VEGF 0.061987 cm3/cm3 tissue Calculated
Skeletal muscle nuclear domain (SMND) surface area 1850 μm2 [6]BMC Systems Biology 2008, 2:77 http://www.biomedcentral.com/1752-0509/2/77
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macromolecule permeability is available [29,30]. When
the tumor/blood permeability is fixed at a specific value,
4 × 10-7 cm/s is assumed.
Summary of experimental measurements of VEGF 
concentration
A meta-analysis was performed by Kut et al. [11]. In breast
cancer, plasma VEGF levels were 2 to 10 times higher that
those in healthy subjects (37 – 310 vs. 27 – 30 pg·mL-1).
In prostate cancer, plasma VEGF levels were 3 to 10 times
higher and in colorectal cancer about two times higher
that those in healthy controls.
For a VEGF molecular weight of 45 kDa, the plasma levels
in breast cancer patients correspond to 0.82 – 6.89 pM
while they are in the range of 0.59 – 0.65 pM for healthy
subjects. In our study, we therefore assume a VEGF plasma
level of around 1 pM in healthy subjects and several-fold
higher in breast cancer patients. The VEGF secretion rates
are then calculated to match the observed plasma level.
Results
In all simulations, unless specified otherwise, the vascular
permeability of healthy tissue is 4 × 10-8 cm/s, the VEGF
plasma clearance 0.0206 min-1 [32], the VEGF165 secretion
rate 0.102 molecule/cell/s in the normal tissue, the VEGF
isoform expression ratio VEGF165:VEGF121 92%:8% [33]
and the density of VEGFR1, VEGFR2 and NRP1 is 10,000
molecules/endothelial cell. These parameter values are
based on currently available experimental data and they
can be altered as additional data become available. In
many cases, we systematically explore the sensitivity of the
results to the parameter variation. VEGF represents the
total VEGF, i.e., VEGF121 and VEGF165. This means that the
Table 2: Kinetic parameters of VEGF in the healthy tissue (human vastus lateralis muscle)
Measured parameters Tissue parameters
Value Unit Value Unit
VEGF binding to VEGFR1
kon 3 107 M-1 s-1 4.8 10-1 (pmol/cm3 tissue)-1 s-1
koff 10-3 s-1
Kd 33 pM 2.0 10-3 pmol/cm3 tissue
VEGF binding to VEGFR2
kon 107 M-1 s-1 1.6 10-1 (pmol/cm3 tissue)-1 s-1
koff 10-3 s-1
Kd 100 pM 6.4 10-3 pmol/cm3 tissue
VEGF165 binding to NRP1
kon 3.2 106 M-1 s-1 5.1 10-2 (pmol/cm3 tissue)-1 s-1
koff 10-3 s-1
Kd 312 pM 2.0 10-2 pmol/cm3 tissue
VEGF165 binding to GAGs
kon 4.2 105 M-1 s-1 6.7 10-3 (pmol/cm3 tissue)-1 s-1
koff 10-2 s-1
Kd 24 nM 1.5 pmol/cm3 tissue
Coupling of NRP1 & VEGFR2
kcV165R2, N1 3.1 1013 (mol/cm2)-1 s-1 2.8 10-1 (pmol/cm3 tissue)-1 s-1
koffV165R2,N1 10-3 s-1
kcV165N1,R2 1014 (mol/cm2)-1 s-1 9.2 10-1 (pmol/cm3 tissue)-1 s-1
koffV165N1,R2 10-3 s-1
VEGFR1 coupling to NRP1
kcR1,N1 1014 (mol/cm2)-1 s-1 9.2 10-1 (pmol/cm3 tissue)-1 s-1
kdissocR1,N 10-2 s-1
VEGFR internalization
kint,R 2.8 10-4 s-1
kint,C 2.8 10-4 s-1
The derivation of these parameters is found in [6]. In this table, 6.24 107 (pmol/cm3 tissue)/M and 1.09 1014 (pmol/cm3 tissue)/(mol/cm2 EC). Here, M 
= moles/liter available interstitial fluid volume.BMC Systems Biology 2008, 2:77 http://www.biomedcentral.com/1752-0509/2/77
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free VEGF concentration corresponds to the sum of the
free VEGF165 and the free VEGF121 concentrations. Simi-
larly, the VEGF secretion rate represents the sum of the
secretion rates of the two VEGF isoforms.
Healthy subject (no diseased compartment)
Without VEGF clearance, steady-state blood and tissue 
concentrations are the same
A range from 0.02 to 0.20 molecule/cell/s was tested for
VEGF165 secretion rate. In the absence of plasma clearance,
the free VEGF concentration in both compartments is
close to directly proportional (R2 = 0.9973) to the VEGF
secretion rate in the normal tissue for the range we tested
(Figure 2A). In the absence of plasma clearance, the
steady-state total VEGF concentration in the blood plasma
equals that in the available interstitial fluid of the healthy
tissue (i.e., diffusible VEGF contained in the accessible
part of the fluid in the healthy tissue). This is in agreement
with  V  equation (26) which, at steady state, becomes
. If 1 pM (1 pmole/L of availa-
ble interstitial fluid) of free VEGF concentration is present,
at steady state, in the normal tissue available interstitial
fluid, a VEGF concentration in the blood will also be 1 pM
(1 pmole/L of blood plasma).
In the absence of plasma clearance, the steady-state free
VEGF concentrations in both compartments are inde-
pendent of the permeability value as long as this value is
non-zero (data not shown). This is because the permeabil-
ity affects the dynamics of the system by regulating how
fast the compartments reach the steady state but not the
steady-state free VEGF concentrations themselves. Look-
ing at equations (28) and (29), in the absence of the
tumor compartment and of plasma clearance, the steady-
state free VEGF concentration does not depend on the per-
meability between the healthy tissue and the blood since
 is assumed. The equation reads
. In other words, the relationship
 holds independently of the
permeability value as long as   holds true.
VV
pA V N
V N
KAV N [] == []
[]
, ,
kk pV
NB
pV
BN =
V
B
Up
UB
V N
KAV N []=
[]
,
VV
pA V N
V N
KAV N [] == []
[]
, ,
kk pV
NB
pV
BN =
Table 3: VEGF concentration and receptor densities for the healthy tissue (human vastus lateralis)
Measured parameter Tissue model
Value Unit Value Unit
Free VEGF concentration
Human vastus lateralis, rest 1 pM 6.2 10-5 pmol/cm3 tissue
Total VEGF tissue concentration
Human vastus lateralis, rest 1–2 pg/μg protein 3.4–6.9 pmol/cm3 tissue
VEGFR1 tissue concentration
Human vastus lateralis, rest 1.6–1.8 pg/μg protein 1.1–1.2 pmol/cm3 tissue
60,000–68,000 #/EC
VEGFR2 tissue concentration
Human vastus lateralis, rest 0.33–0.5 pg/μg protein 0.24–0.34 pmol/cm3 tissue
13,000–19,000 #/EC
NRP1 tissue concentration
0.018–1.8 pmol/cm3 tissue
1,000–100,000 #/EC
ECM binding site density
ECM 0.75 μM 46 pmol/cm3 tissue
Vessel BM 13 μM 1 pmol/cm3 tissue
Myocyte BM 13 μM 4 pmol/cm3 tissue
The conversion of receptor densities to tissue concentrations is based on the relationship mentioned in table 2, and the surface area of an 
endothelial cell, 1000 μm2. VEGF concentration is normalized based on the entire interstitial space, since it diffuses throughout: 6.2 107 (pmol/cm3 
tissue)/M (here, M = moles/liter interstitial space). VEGF binding sites in the ECM and BMs are based on those volumes: 6.2 107 (pmol/cm3 tissue)/
M(ECM), 5.7 104 (pmol/cm3 tissue)/M(EBM), 3.1 105 (pmol/cm3 tissue)/M (MBM). For example, M(EBM) = moles/liter endothelial basement 
membrane. Conversions from pg/mg protein are based on 155 mg protein/g of tissue and 45 kDa VEGF, 210 kDa VEGFR1, 240 kDa VEGFR2 [6].BMC Systems Biology 2008, 2:77 http://www.biomedcentral.com/1752-0509/2/77
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Plasma clearance reduces blood VEGF concentration
The VEGF half-life in plasma has been shown to be 33.7 ±
13.7 min [32]. To explore the effect of the half-life, the
plasma clearance rate cV was chosen between 0.0146 and
0.0347 min-1.
With the introduction of a clearance rate cV of 0.0206 min-
1 (corresponding to a VEGF half-life of 33.7 min), the
steady-state concentration of free VEGF in plasma
becomes 4.5 times lower than in available interstitial fluid
at a vascular permeability of 4 × 10-8 cm/s and 1.3 times
lower at a permeability of 4 × 10-7 cm/s (Figure 2A). The
dependence on VEGF secretion rate is approximately lin-
ear for the range studied. Unlike free VEGF concentration
in normal tissue, free VEGF concentration in the blood is
strongly dependent on the vascular permeability. This is
because, at steady state, the permeability coefficients do
not cancel out in the equations (28) and (29).
Next, the clearance rate is fixed at 0.0206 min-1. The
VEGF165 secretion rate in the healthy tissue is chosen to be
0.102 molecule/cell/s so that, at steady state, there is 1 pM
of free VEGF in the blood for a vascular permeability of 4
× 10-8 cm/s. We investigate the dependence on permeabil-
ity in a range 4 × 10-9 to 4 × 10-6 cm/s. At steady state, the
free VEGF concentration in the available interstitial fluid
in the normal tissue is around 4.5 pM independent of the
permeability (Figure 2B). At very low permeability (4 ×
10-9 to 4 × 10-8 cm/s), very few VEGF molecules secreted in
the normal tissue enter the blood compartment. Because
the clearance is directly proportional to the VEGF concen-
tration in the blood plasma (Equations (28) and (29)), a
few molecules of VEGF are cleared from the blood. There-
fore, the internalization is very high and accounts for most
of the loss of VEGF in the normal tissue. At very high per-
meability (4 × 10-7 to 4 × 10-6 cm/s), a high concentration
of free VEGF enters the blood compartment and is cleared.
The internalization is smaller and the plasma clearance is
responsible for most of the loss of VEGF. In the physiolog-
ical range (4 × 10-8 to 4 × 10-7 cm/s), the free VEGF con-
centration in the blood plasma is roughly proportional to
the permeability between the two compartments. In the
c
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Table 4: Geometric parameters for the breast tumor
Value Unit Reference
Cancer cells
Tumor cells external diameter 17 μm[ 4 3 ]
Volume of one cell 2572 μm3 [4]
Surface area of one cell 997 μm2 [4]
Microvessels
Average luminal diameter 10.3 μm[ 4 4 , 4 5 ]
Endothelial cell thickness 0.5 μm[ 4 ]
Average external diameter 11.3 μm[ 4 ]
Cross sectional area of one vessel 100.3 μm2 [4]
Perimeter of one vessel 43.7 μm[ 4 ]
Volume fractions
Interstitial space 61.1% cm3/cm3 tissue [46,47]
Cancer cells 37% cm3/cm3 tissue [4]
Microvessels 2.4% cm3/cm3 tissue [4]
of which intravascular space 2% [4]
Surface areas
Tumor cells 1416 cm2/cm3 tissue [4]
Microvessels 105 cm2/cm3 tissue [4]
Basement membranes (BM)
Thickness of tumor cell BM 30 nm [4]
Basement membrane volume (tumor cells) 0.00388 cm3/cm3 tissue Calculated
of which available to VEGF 0.002446 cm3/cm3 tissue Calculated
Thickness of microvessel BM 50 nm [4]
Basement membrane volume (microvessels) 0.00043 cm3/cm3 tissue Calculated
of which available to VEGF 0.000270 cm3/cm3 tissue Calculated
Extracellular matrix volume 0.6062 cm3/cm3 tissue Calculated
of which available to VEGF 0.519308 cm3/cm3 tissue CalculatedBMC Systems Biology 2008, 2:77 http://www.biomedcentral.com/1752-0509/2/77
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healthy tissue, however, the change in the net flow
(expressed in moles of VEGF per unit time) from the
healthy tissue to the blood due to permeability changes is
balanced by slight changes in the binding to and the inter-
nalization of VEGF by the receptors; thus, the healthy tis-
sue VEGF concentration vary slightly with the vascular
permeability.
Next, we explore the sensitivity of the results to plasma
clearance in a range between 0.0146 and 0.0347 min-1.
The internalization of VEGF by the receptors in healthy
tissue regulates VEGF concentration in the compartment
(figure 2C). In the blood, however, the VEGF molecules
can accumulate if the clearance rate is decreased (i.e.,
longer half-life).
Transient effects of acute exercise
Given the clearance rate (0.0206 min-1 [32]), vascular per-
meability (4 × 10-8 cm/s) and VEGF165:VEGF121 expression
ratio (92%:8%), the model predicts that a VEGF165 secre-
tion rate of 0.102 molecule/cell/s is necessary to achieve a
free VEGF plasma level of 1 pM, as reported under physi-
ological conditions [11]. This leads to a free VEGF concen-
tration in the normal tissue of approximately 4.5 pM.
To study the VEGF transient effects, we simulate a physical
exercise experiment. Jensen et al. have shown that a 3-
hour two-legged knee extension upregulates VEGF mRNA
by about 3.5 fold for at least 6 hours [13]. VEGF mRNA
levels return to baseline between 6 and 24 hours [13]. We
assume a direct correlation between mRNA and VEGF
protein level. Figure 3A shows the transient effect on free
VEGF concentration in available interstitial fluid and in
blood plasma. The free VEGF concentrations return to
baseline within 6 hours of cessation of the secretion
upregulation (Figure 3A). It is interesting to note that the
fold increase in blood and tissue concentrations are the
same (Figure 3B). However, there is a time lag between the
Table 5: Kinetic parameters of VEGF in tumor (breast cancer)
Measured parameters Tissue parameters
Value Unit Value Unit
VEGF binding to VEGFR1
kon 3 107 M-1 s-1 5.8 10-2 (pmol/cm3 tissue)-1 s-1
koff 10-3 s-1
Kd 33 pM 1.7 10-2 pmol/cm3 tissue
VEGF binding to VEGFR2
kon 107 M-1 s-1 1.9 10-2 (pmol/cm3 tissue)-1 s-1
koff 10-3 s-1
Kd 100 pM 5.2 10-2 pmol/cm3 tissue
VEGF165 binding to NRP1
kon 3.2 106 M-1 s-1 6.1 10-3 (pmol/cm3 tissue)-1 s-1
koff 10-3 s-1
Kd 312 pM 1.6 10-1 pmol/cm3 tissue
VEGF165 binding to GAGs
kon 4.2 105 M-1 s-1 8.1 10-3 (pmol/cm3 tissue)-1 s-1
koff 10-2 s-1
Kd 24 nM 12.5 pmol/cm3 tissue
Coupling of NRP1 & VEGFR2
kcV165R2,N1 3.1 1013 (mol/cm2)-1 s-1 2.9 1011 (pmol/cm3 tissue)-1 s-1
koffV165R2,N1 10-3 s-1
kcV165N1,R2 1014 (mol/cm2)-1 s-1 9.5 1011 (pmol/cm3 tissue)-1 s-1
koffV165N1,R2 10-3 s-1
VEGFR1 coupling to NRP1
kcR1,N1 1014 (mol/cm2)-1 s-1 9.5 1011 (pmol/cm3 tissue)-1 s-1
kdissocR1,N1 10-2 s-1
VEGFR internalization
kint,R 2.8 10-4 s-1
kint,C 2.8 10-4 s-1
The derivation of these parameters can be found in [4]. In this table, 5.22 108 (pmol/cm3 tissue)/M and 1.05 1014 (pmol/cm3 tissue)/(mol/cm2 EC). 
Here, M = moles/liter interstitial space.BMC Systems Biology 2008, 2:77 http://www.biomedcentral.com/1752-0509/2/77
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blood and normal tissue; in transition periods, VEGF lev-
els measured in plasma and tissue samples could be sig-
nificantly different. Higher permeability would decrease
this time lag (data not shown). This provides important
insights on monitoring VEGF protein levels in the case of
exercise training. This simulation demonstrates that VEGF
tissue concentration can increase several-fold during pro-
longed exercise, thus providing a stimulus for exercise-
induced angiogenesis.
Cancer patient (normal tissue, blood and tumor 
compartments)
In this simulation, a 4-cm diameter tumor located in the
breast is represented by the diseased tissue compartment.
The characteristics of this new compartment are presented
in tables 4, 5, 6.
The compilation of the VEGF levels in healthy subjects
and cancer patients [11] has revealed that cancer patients
show, on average, a several-fold increase in their free
VEGF blood plasma levels. This part of the study investi-
gates the possible origins of this increase.
Blood and normal tissue VEGF levels are not significantly sensitive to 
tumor VEGF secretion
We performed a sensitivity analysis on the tumor VEGF
secretion rate. For the selected parameters we found that
regardless of the vascular permeability in the tumor, free
VEGF concentration in available interstitial fluid in the
normal tissue is insensitive to the VEGF secretion rate in
the tumor and to the vascular permeability of the tumor
(Figures 4A). This qualitative behavior is independent of
the density of the NRP1 in the tumor. At a vascular perme-
ability in the tumor of 4 × 10-7 cm/s (dotted lines), the free
VEGF level in the available tumor interstitial fluid is
approximately proportional to the secretion rate of VEGF
in the tumor while the VEGF concentration in the blood
plasma is rather insensitive to the change in the tumor
VEGF secretion. When increasing the permeability by two
orders of magnitude (4 × 10-5 cm/s, dashed lines), more
VEGF molecules secreted from the tumor enter the blood.
This results in an increase of VEGF level in the blood
plasma and a decrease of VEGF level in the tumor for a
given VEGF secretion rate in tumor. However, even at a
high VEGF secretion rate in the tumor, the plasma VEGF
concentration increases by less that 50%. Thus, an
increase in the VEGF secretion rate alone cannot explain
the several-fold increase reported for cancer patients [11],
at least for the selected parameters of the model. For a
given secretion rate in tumor, our calculations show that
for the plasma VEGF level to double, the tumor size would
have to increase approximately to 25-cm diameter.
We now set the tumor VEGF165 secretion rate at 0.076 or
0.025 molecule/cell/s for 10,000 and 100,000 NRP1 in
the tumor respectively, so that, at a vascular permeability
Table 6: VEGF concentration and receptor densities for the tumor (breast cancer)
Measured parameter Tissue model
Value Unit Value Unit
Free VEGF concentration
Breast cancer 0.5–1.5 pM 2.6–7.83 10-4 pmol/cm3 tissue
Total tumor VEGF
Breast cancer 13 pg/mg tumor 0.3 pmol/cm3 tissue
VEGFR1 tissue concentration
102–105 #/EC 1.7 10-3–1.7 100 pmol/cm3 tissue
VEGFR2 tissue concentration
104 #/EC 1.7 10-1 pmol/cm3 tissue
NRP1 tissue concentration
103–106 #/EC 1.7 10-2-1.7 101 pmol/cm3 tissue
ECM binding site density
ECM 0.75 μM 389 pmol/cm3 tissue
Vessel BM 13 μM4 p m o l / c m 3 tissue
Tumor cell BM 13 μM 32 pmol/cm3 tissue
The conversion of receptor densities to tissue concentrations is based on the relationship mentioned in table 5, and the surface area of an 
endothelial cell, 1000 μm2. VEGF concentration is normalized based on the entire interstitial space, since it diffuses throughout: 5.2 108 (pmol/cm3 
tissue)/M (here, M = moles/liter interstitial space). VEGF binding sites in the ECM and BMs are based on those volumes: 5.2 108 (pmol/cm3 tissue)/
M(ECM), 2.7 105 (pmol/cm3 tissue)/M(EBM), 2.5 106 (pmol/cm3 tissue)/M(PBM) [4].BMC Systems Biology 2008, 2:77 http://www.biomedcentral.com/1752-0509/2/77
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in tumor of 4 × 10-8 cm/s (which corresponds to the vas-
cular permeability of healthy tissue), the steady-state free
VEGF concentration in the available interstitial fluid in
the tumor corresponds to that in the available interstitial
fluid in the normal tissue (~4.5 pM).
Increasing vascular permeability of tumor decreases tumor VEGF 
levels
We then perform a sensitivity analysis on the vascular per-
meability in the tumor (range from 4 × 10-8 to 4 × 10-5 cm/
s). We find that the free VEGF concentration in the normal
tissue remains constant independently of the tumor vas-
cular permeability (Figure 4B). The two main reasons are:
the normal tissue volume overwhelms the effects of
smaller volumes (tumor) and the vascular permeability in
the healthy tissue is small. However, the vascular permea-
bility in tumor has a high impact on the free VEGF con-
centration in the tumor as shown in figure 4B. For
permeability higher than 4 × 10-7 cm/s, the free VEGF level
drops drastically in the tumor. This behavior is the result
of the amount of VEGF molecules being cleared from the
blood as they are transported from the tumor to the blood
compartment. The plasma VEGF level is not highly
affected by the increase of vascular permeability in the
tumor because the clearance is directly proportional to the
concentration and because the volume of the healthy tis-
sue is bigger than that of the tumor. In any case, the
plasma VEGF level does not exhibit a several-fold increase
compared to the absence of tumor, even at high permea-
bility (4 × 10-5 cm/s which is an upper range of vascular
permeability for VEGF in tumor found in the literature).
This means that the vascular permeability in tumor
increase alone cannot explain the several-fold increase of
plasma VEGF level in cancer patients [11].
Over a range of clearance rates from 0.0146 and 0.0347
min-1 [32], there is little variation in the free VEGF concen-
tration (Figure 4C) and this also cannot explain the sev-
eral-fold increase in plasma VEGF reported in cancer
patients [11]. Increasing the NRP1 density in the tumor by
an order of magnitude only decreases the tumor VEGF at
high vascular permeability in tumor.
Increasing vascular permeability of healthy tissue increases blood and 
tumor VEGF levels
For high vascular permeability of healthy tissue (4 × 10-6
cm/s – higher than that observed in vivo), the free VEGF
concentration in plasma would be increased approxi-
Blood VEGF, but not tissue VEGF concentration, is dependent on VEGF clearance and vascular permeability Figure 2
Blood VEGF, but not tissue VEGF concentration, is dependent on VEGF clearance and vascular permeability. 
The diseased compartment is not included here. A, Tissue and blood VEGF concentrations increase with VEGF secretion rate. 
The profile is approximately linear in each case. In the absence of VEGF clearance from the blood, the steady-state free VEGF 
concentration is the same in the tissue and in the blood (purple line). With a clearance rate of cV = 0.0206 min-1, the blood con-
centration (red line) is lower than that of the normal tissue (blue dots), which is unchanged by the clearance. Increase in tissue-
blood permeability from kp = 4 × 10-8 cm/s (dotted line) to 4 × 10-7 cm/s (dashed line), raises the blood VEGF concentration 
but not the tissue concentration. B, Increasing transcapillary permeability increases the blood VEGF concentration at steady 
state. VEGF165 secretion rate q = 0.102 molecule/cell/s, clearance rate cV = 0.0206 min-1 [28]. C, Increased clearance rate of 
VEGF from the blood decreases blood concentration of VEGF, without decreasing tissue VEGF. VEGF165 secretion rate q = 
0.102 molecule/cell/s, vascular permeabilities kp = 4 × 10-8 cm/s (dotted line) and 4 × 10-7 cm/s (dashed line). For all simulations, 
VEGFR1 = 10,000, VEGFR2 = 10,000 and NRP1 = 10,000 molecules/endothelial cell.BMC Systems Biology 2008, 2:77 http://www.biomedcentral.com/1752-0509/2/77
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mately four- to five-fold compared to baseline (Figure
4D). Therefore, the vascular permeability of healthy tissue
may increase at sites distant from the tumor (possibly due
to a feed-forward effect of VEGF-induced vascular perme-
ability), leading in turn to a total increase of VEGF con-
centration in the plasma or the additive effects of
increased VEGF secretion, vascular permeability in tumor,
and tumor mass may explain the several-fold increase in
plasma VEGF in cancer patients as reported in the litera-
ture [11].
Distribution of free vs. receptor- and HSPG-bound VEGF in healthy 
and diseased tissues
In the above sections, we presented results of computer
simulations for free VEGF in the tissue and blood com-
partments. To understand the total balance of VEGF in the
body, it is also important to assess the amounts of VEGF
bound to the receptors on the endothelial cells and to the
HSPG sites in the ECM and basement membranes. The
VEGF distribution is shown in Figure 5A. For the parame-
ters specified in the legend, 93% of total VEGF in the
healthy tissue is VEGF165. The model revealed that up to
half of the VEGF distribution in the healthy tissue and the
tumor with 100,000 NRP1 per endothelial cell, is in the
form of a complex where VEGF165 is bound to VEGFR2
and NRP1 simultaneously. In the tumor, 41 to 68%
(depending on the NRP1 density) of the VEGF popula-
tion, is VEGF165 bound to the ECM while it represented
only a quarter in the healthy tissue. Finally, the vast
majority of free VEGF in the blood is VEGF165 (91%),
regardless of the density of NRP1 in the tumor.
The majority of cell surface receptors in healthy tissue and tumor 
receptors are not ligated
The receptor occupancy in the tumor with density of
10,000 NRP1 per endothelial cell is qualitatively similar
to that in the healthy tissue (Figure 5B). In these tissues,
most VEGFR1 and most NRP1 are present as the VEGFR1-
NRP1 complex. Most VEGFR2 is unbound. The majority
of ligated VEGFR2 is in the VEGF165-VEGFR2-NRP1 com-
plex. A ten-fold increase in NRP1 density in the tumor
causes uncomplexed NRP1 to dominate.
Concentration of free receptors and matrix components
Figure 6A compares the concentration of free receptors
and free matrix components. In particular, we see that
VEGF distribution during exercise training Figure 3
VEGF distribution during exercise training. The diseased compartment is not included here. Basal VEGF165 secretion 
rate q = 0.102 molecule/cell/s; clearance rate cV = 0.0206 min-1 [28]; vascular permeability for VEGF kp = 4 × 10-8 cm/s; VEGFR1 
= 10,000, VEGFR2 = 10,000, NRP1 = 10,000 molecules/endothelial cell. Simulation of a 3-hour two-legged knee extension that 
has been shown to upregulate VEGF mRNA by about 3.5 fold for at least 6 hours [13]. A, Free VEGF concentration in tissue 
and blood. Six hours after upregulated secretion ceases, the free VEGF concentration returns to baseline. B, Fold increase in 
free VEGF concentration. The fold increase of VEGF level in the blood is equal to that in the interstitial available fluid. There is 
a lag of response in the blood compartment.BMC Systems Biology 2008, 2:77 http://www.biomedcentral.com/1752-0509/2/77
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Whole-body changes in response to VEGF secretion by a tumor Figure 4
Whole-body changes in response to VEGF secretion by a tumor. The diseased compartment represents a 4-cm diam-
eter tumor. Vascular permeability of the healthy tissue,   = 4 × 10-8 cm/s; VEGF plasma clearance cV = 0.0206 min-1 [28]; 
VEGFR1 = 10,000 and VEGFR2 = 10,000 molecules/endothelial cell; NRP1 = 10,000 molecules/endothelial cell in the healthy 
tissue; VEGF165 secretion rate in healthy tissue qN = 0.102 molecule/cell/s; tumor VEGF165 secretion rate qD = 0.076 or 0.025 
molecule/cell/s for 10,000 (black lines) or 100,000 (dark yellow lines) NRP1 in tumor respectively. The normal tissue VEGF 
level is insensitive to the variation of each of the parameters considered here. A, The free VEGF concentration in the tumor 
and in the blood are approximately linearly dependent on tumor VEGF secretion rate. The tumor VEGF level decreases while 
the blood VEGF level increases when increasing the vascular permeability in tumor from   = 4 × 10-7 cm/s (dotted lines) to 
4 × 10-5 cm/s (dashed lines). B, Increasing vascular permeability in tumor decreases free VEGF in the tumor and slightly 
increases blood VEGF. Increasing the NRP1 receptor density increases the VEGF level in tumor for vascular permeability in 
tumor higher than 4 × 10-7 cm/s. C, Decreasing the clearance rate of VEGF increases free VEGF in the blood and tumor. 
Increasing the density of NRP1 receptors in the tumor has an effect only for higher permeability   = 4 × 10-5 cm/s, drastically 
lowering free VEGF concentration in the tumor. D, Increasing vascular permeability in the healthy tissue results in increased 
free VEGF in the blood and tumor by several-fold. Vascular permeability in the tumor   = 4 × 10-7 cm/s.
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most of available binding sites are in the ECM, EBM and
PBM. The available binding site concentrations of the
matrix components are independent of the NRP1 density
in the tumor.
Relative probabilities of VEGF binding to receptors and matrix 
components
The relative probabilities are expressed as concentration
divided by Kd. The propensity to bind to VEGFR1 and
VEGFR2 is much higher in healthy tissue than in tumor
(Figure 6B). In particular, the higher the NRP1 density in
tumor, the less the binding to VEGFR1 and VEGFR2.
However, the propensity to bind to NRP1 is much higher
in tumor for a density of 100,000 NRP1 per endothelial
cell. The probability to bind to the ECM is much higher
than that of binding to the PBM or EBM because the vol-
ume of ECM is bigger.
Flows of VEGF in the body at steady state
Figure 7 shows the flows (moles of VEGF per unit time) in
the compartments normalized to the number of moles of
VEGF secreted per unit time in the healthy tissue. We first
consider a healthy subject (no diseased tissue compart-
ment). In the absence of clearance, at steady state, there is
as much VEGF secreted as internalized (Figure 7A). There
is no net flow between the normal tissue and the blood.
This configuration corresponds to Figure 2A in the
absence of clearance (purple line). Figure 7B shows the
representation of a cancer patient. At low vascular perme-
ability in the healthy tissue, almost 99.9% secreted VEGF
is internalized at steady state. Because a small fraction of
VEGF from the healthy tissue enters the bloodstream (less
than 0.2%), a small fraction is cleared from the plasma. If
the vascular permeability in the healthy tissue is increased
by an order of magnitude (Figure 7C), a larger percentage
of VEGF enters the bloodstream (0.58%) which leads to a
larger percentage of VEGF cleared from the plasma.
Because the percentage of VEGF extravasating into the
healthy tissue is increased, the internalization of VEGF in
the healthy tissue is only slightly affected by the increase
in vascular permeability in the healthy tissue. Most of
VEGF secreted in the tumor is internalized at steady state.
However, when increasing the vascular permeability in
healthy tissue, some VEGF extravasates into the tumor
canceling out the percentage of VEGF that has entered the
bloodstream from the tumor. Essentially, since the net
flow is zero in this configuration, the diseased compart-
ment does not play any significant role in the VEGF in the
blood or in the healthy tissue. This explains why Figure
4D is similar to Figure 2B.
Discussion
The compartment model described here is a useful tool to
simulate physiological and pathological situations involv-
ing VEGF. It provides informative quantitative biological
details such as VEGF distributions in tissue and in blood
that are currently not accessible by direct experiments, as
well as the sensitivity of VEGF distribution to specific bio-
logical parameters.
Even though, at this stage, the model considers two iso-
forms of the VEGF-A family, the model can be readily
extended to introduce additional factors, such as the iso-
form VEGF189 that could also play an important role in
angiogenesis. For example, it was shown that the VEGF189
represents the highest increase in protein levels amongst
the VEGF-A isoforms in the course of exercise training (3-
fold for VEGF189 compared to 2.2-fold for VEGF165 and
VEGF121) [34]. Receptors and co-receptors could also be
added: soluble VEGFR1 (sFlt-1) or Neuropilin-2 (NRP2),
for example, could also play significant roles in angiogen-
esis. Molecules that do not play a role in angiogenesis but
compete for the receptor binding and therefore alter the
VEGF distribution could also be taken into account. For
instance, the virus-encoded VEGF-E proteins bind with
high affinity to VEGFR2 but do not bind to VEGFR1, and
VEGF-B and PlGF compete with VEGF-A for binding to
VEGFR1 [3].
The model takes into account VEGF receptors on the ablu-
minal surface of the endothelial cells. There is some evi-
dence that these receptors may be present on their
luminal surfaces as well [17]; however, to our knowledge,
no quantification is available. To take these receptors into
account would require the introduction of receptors in the
blood compartment and could potentially change the
dynamics of the system. Since the VEGF secretion rates
were fine-tuned based on the steady-state concentration
of VEGF in the plasma found in the literature [11], the
addition of the VEGF receptors on the luminal surface of
the endothelial cells may therefore require re-adjustment
of the secretion rates values.
For simplicity, healthy tissue is represented as approxi-
mately 65 kg of tissue whose parameters are representative
of human vastus lateralis skeletal muscle, since this is one
of the few tissues characterized. It could be of interest to
add the kidneys or liver and explicitly illustrate clearance
from these organs. More generally, clearance from healthy
tissue could be added. The addition of bones and poorly-
vascularized organs could also play an important role
since secretion of VEGF apparently does not occur in these
tissues. The bone marrow could also be an important
component to add to the model as it is the site where pro-
and anti-angiogenic factors are segregated into separate
platelet α-granules to be transported within the blood-
stream and possibly released at the site of the tumor [35]
thus protecting VEGF from binding to receptors on the
luminal side of the endothelial cells or binding to anti-
VEGF agents present in the bloodstream or extravasating.BMC Systems Biology 2008, 2:77 http://www.biomedcentral.com/1752-0509/2/77
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This crucial point leads to the introduction of the platelets
as well. Not only are platelets a vector for VEGF transport
in the bloodstream, they have also been shown to be a
location where the binding with VEGF monoclonal anti-
bodies, used in anti-angiogenic therapies, takes place [36].
Due to lack of experimental data in vivo, we consider kint
to be the same in tumor and normal tissues. Experimental
evaluation of the internalization rates of the receptors in
vivo in healthy tissue and tumor would improve the accu-
racy of the model.
Distribution of VEGF and its receptors for each tissue Figure 5
Distribution of VEGF and its receptors for each tissue. The diseased compartment represents a 4-cm diameter tumor. 
Vascular permeability of healthy tissue,   = 4 × 10-8 cm/s; vascular permeability of the tumor   = 4 × 10-7 cm/s; VEGF 
plasma clearance cV = 0.0206 min-1 [28]; VEGFR1 = 10,000 and VEGFR2 = 10,000 molecules/endothelial cell; NRP1 = 10,000 
molecules/endothelial cell in the healthy tissue; VEGF165 secretion rate in healthy tissue qN = 0.102 molecule/cell/s; tumor 
VEGF165 secretion rate qD = 0.076 or 0.025 molecule/cell/s for 10,000 (written in black) or 100,000 (written in dark yellow) 
NRP1 in tumor respectively. A, From center out, discs represent: total VEGF, VEGF121 and VEGF165 distributions. In the 
healthy tissue, about half of the total VEGF distribution is in the form of the ternary complex VEGF165 bound to VEGFR2 and 
NRP1, leaving 24% bound to the ECM. In the tumor, most total VEGF is bound to the ECM (68% and 41% for 10,000 and 
100,000 NRP1 in tumor, respectively). Most of the remaining total VEGF population is in the form of the ternary complex 
VEGF165 bound to VEGFR2 and NRP1 (15% and 48% for 10,000 and 100,000 NRP1 in tumor, respectively). Most of VEGF121 
isoform is bound to VEGFR1 and NRP1 simultaneously. The vast majority of the free VEGF distribution in the blood is in the 
isoform VEGF165 (91%). B, Receptor occupancy. From center out, discs represent: overall receptor, NRP1, VEGFR2, VEGFR1 
occupancies. The initial receptor densities dictate the receptor occupancies. For identical NRP1 receptor densities (10,000), 
the healthy tissue and the tumor have the same receptor occupancies: 60% of all the receptors are in their free states and 33% 
are in the complex form VEGFR1-NRP1. If the NRP1 density is increased by 10-fold in the tumor, most of the total receptors 
are free NRP1 (81%) and a small fraction is bound to VEGFR1 (9%).
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Concentration of free receptors and matrix components and relative probabilities of VEGF binding Figure 6
Concentration of free receptors and matrix components and relative probabilities of VEGF binding. The dis-
eased compartment represents a 4-cm diameter tumor. Vascular permeability of the healthy tissue,   = 4 × 10-8 cm/s; vascu-
lar permeability in the tumor   = 4 × 10-7 cm/s; VEGF plasma clearance cV = 0.0206 min-1 [28]; VEGFR1 = 10,000 and 
VEGFR2 = 10,000 molecules/endothelial cell; NRP1 = 10,000 molecules/endothelial cell in the healthy tissue; VEGF165 secretion 
rate in healthy tissue qN = 0.102 molecule/cell/s; tumor VEGF165 secretion rate qD = 0.076 or 0.025 molecule/cell/s for 10,000 
(black bars) or 100,000 (dark yellow bars) NRP1 in tumor respectively. A, Concentration of free receptors and matrix compo-
nents. For the same NRP1 density in both tissues, the healthy tissue and tumor have the same concentration of free receptors. 
The occupancy of the matrix components (ECM, PBM, EBM) is insensitive to the NRP1 density in the tumor. B, Relative prob-
abilities of VEGF binding to receptors and matrix components (concentration/Kd). The propensity to bind to receptors is much 
higher in healthy tissue than in tumor. The likelihood of binding to the matrix components, however, is very similar in the 
healthy tissue and tumor regardless of the NRP1 density.
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Flows of VEGF in the body at steady state Figure 7
Flows of VEGF in the body at steady state. The flows are normalized to the moles of VEGF secreted per unit time in the 
normal tissue. Units before normalization: moles/s. VEGF165 secretion rate in healthy tissue qN = 0.102 molecule/cell/s; VEGFR1 
= 10,000, VEGFR2 = 10,000 molecules/endothelial cell; NRP1 = 10,000 molecules/endothelial cell in the healthy tissue. A, In 
the absence of diseased tissue and clearance, the internalization of VEGF balances the secretion. There is no net flow between 
the two compartments. Vascular permeability of the healthy tissue,   = 4 × 10-8 cm/s; B, In the presence of a tumor and of 
VEGF clearance, most VEGF that has been secreted is internalized after binding to receptors (99.866%). A small fraction pene-
trates the bloodstream. Most of VEGF secreted in the tumor is being internalized after binding to receptors (99.150%). This 
configuration corresponds to low vascular permeability in healthy tissue in Figure 4D. The diseased compartment represents a 
4-cm diameter tumor; vascular permeability of the healthy tissue,   = 4 × 10-8 cm/s; vascular permeability in the tumor   
= 4 × 10-7 cm/s; VEGF165 secretion rate in tumor qD = 0.076 molecule/cell/s; VEGF plasma clearance cV = 0.0206 min-1 [28]; 
NRP1 = 100,000 molecules/endothelial cell in the tumor. C, At higher vascular permeability in the healthy tissue   = 4 × 10-
6 cm/s, the net flow of VEGF entering the bloodstream from the healthy tissue increases to 0.580%. The internalization of 
receptors in the healthy tissue decreases (99.420%) while the internalization of receptors in the tumor increases (99.861%). 
This configuration corresponds to high vascular permeability in healthy tissue in Figure 4D. The diseased compartment repre-
sents a 4-cm diameter tumor; vascular permeability   = 4 × 10-7 cm/s in the tumor and   = 4 × 10-8 cm/s in healthy tissue; 
VEGF165 secretion rate in tumor qD = 0.076 molecule/cell/s; VEGF plasma clearance cV = 0.0206 min-1; NRP1 = 100,000 mole-
cules/endothelial cell in the tumor.
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In our current model, vascular permeability is independ-
ent of VEGF concentration. However, VEGF increases per-
meability in pathological angiogenesis where the blood
vessels become leaky. Therefore, the model should define
the permeability as a function of the VEGF concentration.
Another factor that could be significant is the transport of
VEGF via the lymphatics.
Conclusion
A compartmental model was formulated to represent
both VEGF transport throughout the entire human body
and the distribution of free and bound VEGF at the molec-
ular level in tissues. Blood and tissue are interconnected
by vascular permeability for VEGF transport.
In the healthy subject, in the absence of clearance, free
VEGF in the plasma follows that in the available intersti-
tial fluid volume in the healthy tissue. When clearance is
introduced, free VEGF levels in tissue and blood are still
approximately proportional to the VEGF secretion rate.
However, free VEGF concentration is lower in plasma
than in tissue. We also demonstrated that the internaliza-
tion of the receptors decreases as the permeability
increases, maintaining the free VEGF level constant in the
normal tissue while the concentration in the blood
increases as well.
The model was used to determine variations of VEGF lev-
els during an exercise training experiment. We simulated
a 3-hour two-legged knee extension, studied by Jensen et
al. [13]. After a 6-hr upregulation of VEGF secretion, the
VEGF concentration returns to baseline after another 6
hours, assuming proportionality between mRNA and
VEGF protein level. The model predicted a time lag in
VEGF levels between tissue and blood during the transi-
tion periods. This has implications for measurements as
blood samples could exhibit higher VEGF levels than tis-
sue samples.
In pathological cases, a third compartment representing
diseased tissue was added. In our simulations, this dis-
eased tissue was chosen to be a 4-cm diameter tumor
located in the breast. We investigated the possible causes
of the several-fold increase in plasma VEGF in cancer
patients reported in the literature. Free VEGF concentra-
tion in healthy tissue remained constant during all the
performed simulations because the volume of that tissue
was much larger than that of the tumor and the vascular
permeability of healthy tissue is low. The tumor compart-
ment was generally the most sensitive to the change of
VEGF secretion rates in the tumor and the vascular perme-
ability in the tumor. These variations did not affect the
plasma VEGF levels significantly. However, increasing
vascular permeability in healthy tissue increased plasma
VEGF levels, suggesting that, apart from additive effects
(such as an increase in VEGF secretion rate, combined
with higher vascular permeability in the tumor and
increase tumor volume), a change in vascular permeabil-
ity in the healthy tissue could explain the plasma VEGF
increase in cancer patients.
The model revealed that about half of the VEGF distribu-
tion is in the form of a ternary complex where VEGF165 is
bound to VEGFR2 and NRP1. In the tumor, most of the
other half of the VEGF population was VEGF165 bound to
the ECM while it represented only a quarter in the normal
tissue. This led to a low amount of VEGF165 bound to
VEGFR1 and VEGFR2 in the tumor whereas it represents
about 20% in the normal tissue. Most of VEGFR2 is in its
free state while most VEGFR1 and NRP1 are present as the
VEGFR1-NRP1 complex. The available binding site con-
centrations of the matrix components are independent of
the NRP1 density in the tumor. Finally, the model showed
that the higher the NRP1 density in tumor, the less the
binding to VEGFR1 and VEGFR2.
This model has provided new insights on molecular dis-
tribution and biological details that cannot be easily
assessed experimentally. The adaptability of the compart-
mental model allows the simulation of human or animal
subjects and VEGF-dependent diseases as long as the bio-
logical properties of the studied tissue are available. This
model can be extended by including new molecular spe-
cies, taking into account platelets and leukocytes as VEGF
carriers, or biophysical processes that could intervene in
VEGF transport or VEGF binding. In particular, the model
presented here could serve as a basis for devising pro- and
anti-angiogenic therapies and testing their potential
effects on the VEGF distribution in the human body.
Glossary
The units are given for the healthy tissue and tumor com-
partments unless specified.
[species] Concentration of species (in mol/cm3 tissue)
qV VEGF secretion rate (in mol/cm3 tissue/s)
 Permeation rate of VEGF from compartment I  to
compartment J (in cm/s)
SR Insertion rate of the receptors R (in mol/cm3 tissue/s)
kon Association rate constant (in (mol/cm3 tissue)-1/s)
koff Dissociation rate constant (in s-1)
kc Rate constant of cell surface receptor coupling (in (mol/
cm3 tissue)-1/s)
kpV
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kdissoc Dissociation rate constant of coupled receptors (in s-
1)
kint Internalization rate constant for cell surface receptors
(in s-1)
cV Clearance rate of VEGF from the plasma (in s-1)
SIJ Surface between compartment I and compartment J (in
cm2)
UI Volume of compartment I (in cm3)
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